Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Qsymia (phentermine/topiramate) and Mounjaro (tirzepatide) are both medications used to help with weight management, but they have some important differences. Qsymia is a combination of phentermine, a sympathomimetic, and topiramate, an antiepileptic, and is FDA-approved for weight loss in people over 12 living with obesity or are living with overweight and have at least weight-related condition. Mounjaro is a GIP and GLP-1 agonist approved for improving blood sugar control in adults with Type 2 diabetes but is also sometimes used off-label for weight loss. Qsymia is taken orally once a day, while Mounjaro is injected under the skin once a week. Qsymia is a controlled substance due to the phentermine component, whereas Mounjaro is not. Common side effects of Qsymia include dry mouth and constipation, while Mounjaro often causes nausea and diarrhea. Qsymia can cause a fast heart beat, while Mounjaro can increase the risk of some types of thyroid cancers. Both medications can cause problems with vision.
Qsymia (phentermine / topiramate ER)
Mounjaro (tirzepatide)
Qsymia (phentermine / topiramate ER)
Mounjaro (tirzepatide)
Summary of Qsymia vs. Mounjaro
Summary for Sympathomimetic / Antiepileptic
Prescription only
Qsymia (phentermine / topiramate extended release) is a combination medication used to help with weight loss. It's approved for people over 12 who are considered obese and for some adults who are considered overweight. This medication is a tablet that you take once a day. You should also eat a balanced diet and exercise regularly for best results. Side effects include a "pins-and-needles" feeling, dry mouth, and constipation. You can only get this medication through the Qsymia REMS (Risk Evaluation and Mitigation Strategies) program because of the risk of birth defects if taken during pregnancy.